PAVmed | MedPath

Lucid Diagnostics Expands EsoGuard Access Through Concierge Medicine and Secures First Commercial Insurance Coverage

3 months ago

• Lucid Diagnostics has partnered with LEAA Health to offer its EsoGuard Esophageal DNA Test to concierge medicine patients on a cash-pay basis, targeting the growing $10.9 billion concierge medicine market projected by 2032. • Highmark Blue Cross Blue Shield has issued the first positive commercial insurance coverage policy for Lucid's EsoGuard test in New York state, marking a significant milestone that could influence other insurers to follow suit. • The EsoGuard test provides non-invasive screening for esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD), potentially enabling earlier intervention and improved patient outcomes.

EsoGuard Esophageal DNA Test Demonstrates High Clinical Utility in Detecting Barrett's Esophagus

5 months ago

• A new study demonstrates the clinical utility of Lucid Diagnostics' EsoGuard test for detecting Barrett's Esophagus. • The study showed a high patient compliance rate of 85% with referrals to confirmatory upper endoscopy after positive EsoGuard results. • EsoGuard effectively triages patients at increased risk for esophageal precancer, reducing the need for invasive procedures. • The test exhibits near-perfect provider decision impact, with consistent referral patterns based on test results.

IceCure Medical's ProSense Receives Favorable FDA Panel Recommendation

6 months ago

• IceCure Medical's ProSense system received a favorable recommendation from the FDA Medical Device Advisory Committee for treating early-stage, low-risk breast cancer. • The FDA's positive assessment enhances the likelihood of final FDA approval, expected by the end of Q1 2025, potentially catalyzing the system's adoption. • IceCure Medical's financial position is stable, with $10.7 million in cash and no debt as of September 30, 2024, alongside a 98% year-over-year revenue increase in Q3 2024.